Rise of escitalopram and the fall of citalopram.

ABSTRACT:

Introduction

Citalopram and escitalopram are among the most used medications and are key treatments for many psychiatric disorders. Previous findings suggest citalopram and escitalopram prescription rates are changing because of the patent for citalopram ending as opposed to evidence of a clear therapeutic advantage, which is called evergreening. This retrospective study focuses on characterizing the chronologic and geographic variation in the use of citalopram and escitalopram among US Medicaid and Medicare patients. We hypothesized that prescription rates of citalopram will decrease with a concurrent increase in escitalopram, consistent with evergreening.

Methods

Citalopram and escitalopram prescription rates and costs per state were obtained from the Medicaid State Drug U

SUBMITTER: Cavanah LR 

PROVIDER: S-EPMC10197723 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature